(2023)
Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study.
ANTICANCER RESEARCH.
43,
9
(2023)
Tumor mutation burden in gastro-entero-pancreatic- neuroendocrine neoplasms.
JOURNAL OF GASTROINTESTINAL ONCOLOGY.
14,
4
(2023)
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY.
16,
(2023)
Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY.
-,
-
(2023)
Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.
Oncology Research.
31,
6
(2022)
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Clinical Oncology.
34,
8
(2022)
Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07.
JOURNAL OF CLINICAL ONCOLOGY.
40,
33
(2022)
Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer.
ANNALS OF SURGICAL ONCOLOGY.
-,
-
(2022)
HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer.
FRONTIERS IN ONCOLOGY.
12,
(2021)
Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT.
(2021)
Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population- based cohort study.
EUROPEAN JOURNAL OF CANCER.
155,
(2021)
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial.
ANNALS OF ONCOLOGY.
32,
3
(2021)
Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT).
ONCOLOGIST.
-,
-
(2021)
ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy.
IN VIVO.
35,
1
(2021)
Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer.
JOURNAL OF CANCER.
12,
2
(2020)
Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.
12,
(2020)
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection the ARTIST 2 trial.
CLINICAL COLORECTAL CANCER.
19,
3
(2020)
Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors.
EXPERT OPINION ON INVESTIGATIONAL DRUGS.
29,
9
(2020)
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.
12,
-
(2020)
Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer.
CANCER RESEARCH AND TREATMENT.
52,
2
Patent/Intellectual Property
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS}.
11849123.2.
20180808.
SPAIN
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS}.
11849123.2.
20180808.
GERMANY
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS}.
11849123.2.
20180808.
POLAND
Conference Paper
(2008)
A Phase I/II Trial of docetaxel and oxaliplatin in patienes with advanced gastric cancer.
ASCO.
UNITED STATES
(2008)
A Phase II study of oxaliplatin in combination with doxorubicine as first-line chemotherapy in patients with inoperable hepatocellular carcioma..
ASCO.
UNITED STATES
(2006)
Immunotherapy with autologous tumor lysates-pulsed dentritic cells for patients with metastatic renal cell carcinoma..
Annals of Oncology.
TURKEY
(2006)
Phase II Study of Capecitabine and Cisplatin as First -Line Chemotherapy in Patients with Advanced Esophageal Cancer..
Annals of Oncology.
TURKEY
(2006)
Pediatric-type sarcomas in adult patients: Age is an independent prognostic factor in IRS group I/II..
Cancer Research Treatment.
KOREA, REPUBLIC OF
(2006)
Phase II Study od Capectabine and Cisplatin as First-line Chemotherapy in Patients with Advance Esophageal Cancer.
Cancer Research and Treatment.
KOREA, REPUBLIC OF
(2006)
Phase II Study of Capecitabine and Cisplatin in Advanced Biliary Tract Cancer.
Cancer Research and Treatment.
KOREA, REPUBLIC OF
(2006)
A phase II study of irinotecan, oxaliplatin, 5-fluorouracil, leucovorin (FOLFOXIRI) as a first-line chemotherapy in metastatic gastric cancer..
ASCO Annual Metting.
UNITED STATES
(2006)
Pediatric-type sarcomas in adult patients: Age is an independent prognostic factor in IRS group I/II..
Journal of Clinical Oncology.
UNITED STATES
(2006)
A phase II trial of capecitabine plus gemcitabine for advanced pancreatic adenocarcinoma: Analysis of clinical outcomes and CA19-9 response..
Gastrointestinal Cancer Symposium.
UNITED STATES